Last Updated: May 12, 2026

Claims for Patent: 8,273,711

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,273,711

Title:	Topical drug delivery using phosphatidylcholine
Abstract:	The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.
Inventor(s):	Perricone; Nicholas V. (Meriden, CT)
Assignee:	Transdermal Biotechnology, Inc. (Meriden, CT)
Application Number:	13/024,689
Patent Claims:	1. A stable transdermal insulin composition comprising a phosphatidylcholine component, said phosphatidylcholine component comprising polyenylphosphatidylcholine-enriched phosphatidylcholine and at least one polyglycol, and forming a non-liposomal multilamellar liquid crystal carrier entrapping said insulin for transdermal delivery to dermal vasculature, wherein said multilamellar liquid crystal carrier stabilizes the insulin at room temperature, wherein said phosphatidylcholine component comprises 45% w/w phosphatidylcholine, 50% w/w polyglycol having a molecular weight of 200 and 5% w/w polyglycol having a molecular weight of 400. 2. The transdermal composition of claim 1, further comprising a surfactant, and a lubricant, and methyl paraben. 3. The transdermal composition of claim 2, wherein said surfactant is a siloxylated polyether; and said lubricant is silicone fluid. 4. The transdermal composition of claim 3, wherein said siloxylated polyether is dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane; and said silicone fluid contains low viscosity polydimethylsiloxane polymers. 5. A stable transdermal therapeutic composition comprising a phosphatidylcholine component, said phosphatidylcholine component comprising polyenylphosphatidylcholine-enriched phosphatidylcholine and at least one polyglycol, and forming a non-liposomal multilamellar liquid crystal carrier entrapping a therapeutic compound for transdermal delivery to dermal vasculature, wherein said multilamellar liquid crystal carrier stabilizes the therapeutic compound at room temperature, wherein said phosphatidylcholine component comprises 45% w/w phosphatidylcholine, 50% w/w polyglycol having a molecular weight of 200 and 5% w/w polyglycol having a molecular weight of 400. 6. The transdermal composition of claim 5, further comprising a surfactant, and a lubricant, and methyl paraben. 7. The transdermal composition of claim 6, wherein said surfactant is a siloxylated polyether; and said lubricant is silicone fluid. 8. The composition of claim 5, wherein the therapeutic compound is selected from the group consisting of oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, and combinations of any of these. 9. The composition of claim 5, wherein the phosphatidylcholine is pure polyenylphosphatidylcholine. 10. The composition of claim 5, wherein the composition contains about 85% phosphatidylcholine.

Details for Patent 8,273,711

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	⤷ Start Trial	2031-02-10
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	⤷ Start Trial	2031-02-10
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	⤷ Start Trial	2031-02-10
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	⤷ Start Trial	2031-02-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.